Needham analyst Alan Carr downgraded Neurocrine to Hold, saying that the stock looks “fairly valued”. The analyst acknowledges that the launch of Ingrezza in Tardive Dyskinesia has been impressive, but contends that since the management reflected on its likely lack of efficacy in Tourette Syndrome, the program’s long-term success is “already reflected” in the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.